


Imagine Eyes is the leading pioneer in ultrahigh-resolution retinal imaging. With our devices, ophthalmologists examine patients' retinas at the cellular level. We offer highly sensitive biomarkers of retinal diseases for clinical research studies and therapy trials.

## Meet us at ARVO: booth #7002


### De-risk retinal therapy trials

Imagine Eyes brings precision cellular-resolution retinal imaging into natural history studies and clinical trials, delivering biomarkers that reduce risk at every stage of your development program:

- **Select the right patients** with phenotyping information at the level of individual cells
- **Reduce variability** by stratifying patients based on short-term disease progression
- **Evaluate treatment response on short time scales** with outcome measures up to 5 times more sensitive than conventional imaging markers
- **Monitor subclinical adverse effects** at the cellular and microvascular levels



### rtx1™ Adaptive Optics Retinal Camera



### Key figures & customer references

- Team: **20** experts in ophthalmic imaging
- Latest funding: **€4.9m** (European Commission)
- rtx1 image resolution: **3 μm**
- rtx1 acquisition time: **2 secs**
- Adopted by **100+** clinical centers in **20** countries
- Proven by **300+** peer-reviewed publications



### Evidence from peer-reviewed publications

Longitudinal studies using rtx1 have demonstrated the detection of disease progression in 6 months in retinitis pigmentosa (RP)<sup>[1,2,3]</sup> and in less than a month in dry AMD<sup>[4]</sup>. In therapeutic studies, rtx1 has enabled assessing early inflammatory response<sup>[5]</sup> and demonstrating short-term cone photoreceptor rescue<sup>[6]</sup> after gene therapy, and assessing the stability and engraftment of transplanted stem cells in wet AMD and RP<sup>[7,8]</sup>.

### Turnkey implementation with Fully Equipped

Together with our partner Emsere, we offer an end-to-end solution for clinical trials: from site equipment and logistics to imaging hardware, software, and full support for your investigation and reading centers.

### Contacts

[contact@imagine-eyes.com](mailto:contact@imagine-eyes.com)



**Nicolas Chateau, PhD**  
Cofounder & Chief Executive Officer



**Marine Durand**  
Product Manager Retinal Imaging



**Laurent Vabre, PhD**  
Manager Sales & Support

Imagine Eyes SA, 18 rue Charles de Gaulle, 91400 Orsay, France

RTX1 has been approved as a medical device in the EU, Japan, China and South Korea. In the USA, rtx1 has not received the FDA clearance: it is an investigational device that requires institutional review board (IRB) oversight.

© 2026.04 Imagine Eyes S.A all rights reserved.

[1] Roshandel et al., *TVST*, 2021, DOI: 10.1167/tvst.10.14.11

[2] Gocho et al., *IOVS*, 2025, 66(8):3135.

[3] Hiraoka et al., *IOVS*, 2025, 66(8):3163.

[4] Gocho et al., *IOVS*, 2013, DOI: 10.1167/iovs.12-10672

[5] Kortuem et al. *Acta Ophthalmol*, 2023, DOI: 10.1111/aos.15765

[6] Kortuem et al. *Acta Ophthalmol*, 2021, DOI: 10.1111/aos.14990

[7] Takagi et al., *Ophthalmol Ret*, 2019, DOI: 10.1016/j.oret.2019.04.021

[8] Sakai et al., *Ophthalmol Sci*, 2025, DOI: 10.1016/j.xops.2025.100770